On April 25 | SNY.US (SNY.US) rose 5.15% to $49.01. Sanofi's first-quarter revenue was US$11.364 billion, with an earlier value of US$10.971 billion and an expected value of US$11.07 billion; earnings per share were $0.97, compared to the previous value of US$1.16, and the expected value was US$0.94. Among them, Sanofi's hemophilia drug Altuviiio helped drive this performance, and demand for the drug in the US has been unexpectedly strong since its launch in March 2023.
美股异动丨赛诺菲涨5.15% Q1业绩超预期 血友病药物在美国需求强劲
Changes in US stocks 丨 Sanofi rose 5.15%, Q1 performance exceeded expectations, strong demand for hemophilia drugs in the US
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.